U.S. markets close in 4 hours 44 minutes
  • S&P 500

    -43.84 (-1.06%)
  • Dow 30

    -277.21 (-0.81%)
  • Nasdaq

    -214.71 (-1.60%)
  • Russell 2000

    -25.89 (-1.17%)
  • Crude Oil

    +1.23 (+1.88%)
  • Gold

    -10.60 (-0.58%)
  • Silver

    -0.25 (-0.89%)

    -0.0075 (-0.62%)
  • 10-Yr Bond

    +0.0550 (+3.39%)

    -0.0045 (-0.32%)

    +0.8570 (+0.79%)

    +111.08 (+0.20%)
  • CMC Crypto 200

    -52.78 (-3.38%)
  • FTSE 100

    +73.95 (+1.06%)
  • Nikkei 225

    -461.08 (-1.61%)

Introducing AC Immune (NASDAQ:ACIU), The Stock That Slid 66% In The Last Year

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
  • Oops!
    Something went wrong.
    Please try again later.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

AC Immune SA (NASDAQ:ACIU) shareholders should be happy to see the share price up 11% in the last quarter. But that isn't much consolation to those who have suffered through the declines of the last year. Specifically, the stock price slipped by 66% in that time. Some might say the recent bounce is to be expected after such a bad drop. Arguably, the fall was overdone.

View our latest analysis for AC Immune

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

AC Immune managed to increase earnings per share from a loss to a profit, over the last 12 months. Earnings per share growth rates aren't particularly useful for comparing with the share price, when a company has moved from loss to profit. So it makes sense to check out some other factors.

AC Immune managed to grow revenue over the last year, which is usually a real positive. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

NasdaqGM:ACIU Income Statement, July 10th 2019
NasdaqGM:ACIU Income Statement, July 10th 2019

We know that AC Immune has improved its bottom line lately, but what does the future have in store? This free report showing analyst forecasts should help you form a view on AC Immune

A Different Perspective

While AC Immune shareholders are down 66% for the year, the market itself is up 6.4%. While the aim is to do better than that, it's worth recalling that even great long-term investments sometimes underperform for a year or more. Putting aside the last twelve months, it's good to see the share price has rebounded by 11%, in the last ninety days. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. Before forming an opinion on AC Immune you might want to consider these 3 valuation metrics.

But note: AC Immune may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.